Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of il-1[beta] binding antibodies

A technology that combines antibodies and uses, applied in the direction of antibodies, antibody medical components, medical preparations containing active ingredients, etc., can solve problems such as incurable cancer

Pending Publication Date: 2021-08-06
NOVARTIS AG
View PDF84 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Most cancers remain incurable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of il-1[beta] binding antibodies
  • Use of il-1[beta] binding antibodies
  • Use of il-1[beta] binding antibodies

Examples

Experimental program
Comparison scheme
Effect test

example

[0624] The following examples are provided to aid in the understanding of the invention but are not intended and should not be construed as limiting its scope in any way.

example 1

[0626] Tumor-derived IL-1β induces distinct pro-tumor metastasis mechanisms

[0627] Materials and methods

[0628] cell culture

[0629] Human breast cancer MDA-MB-231-Luc2-TdTomato (Calliper LifeSciences, Manchester, UK), MDA-MB-231 (parent) MCF7, T47D (European Authoritative Cell Culture Collection (ECACC)) , MDA-MB-231-IV (Nutter et al., 2014) and bone marrow HS5 (ECACC) and human primary osteoblast OB1 in DMEM+10% FCS (Gibco, Invitrogen, Paisley, cultivated in the UK). All cell lines were cultured in a 5% CO2 humidified incubator and used at a low passage rate of >20.

[0630] tumor cell transfection

[0631] Using an ORF plasmid (OriGene Technologies Inc.), Rockville, from competent Escherichia coli (OriGene Technologies Inc.) , Maryland) purified plasmid DNA was stably transfected into human MDA-MB-231, MCF 7 and T47D cells to overexpress the gene IL1B or IL1R1. Use PureLink TMPlasmid DNA was purified with the HiPure Plasmid Miniprep Kit (ThemoFisher) and quantif...

example 2

[0673] Simulated canaginumab PK profile and hsCRP profile for lung cancer patients.

[0674] Based on data from the CANTOS study, a model was generated to characterize the relationship between canaginumab pharmacokinetics (PK) and hsCRP.

[0675] This study used the following methods: Model building using first-order conditional estimation and interaction methods. The model describes the logarithm of time-resolved hsCRP as:

[0676] y(t ij )=y 0，i +y eff (t ij )

[0677] where y 0，i is the steady-state value and y eff (t ij ) indicates therapeutic effect and depends on systemic exposure. The treatment effect is described by an Emax-type model,

[0678]

[0679] Among them, E max，i is the maximum possible response at high exposure, IC50 i is the concentration at which half of the maximal response is obtained.

[0680] Each parameter E max，i and y 0，i and IC50 i The logarithm of is estimated as the sum of typical values, covariate effect covpar*cov i and a no...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Use of an IL-1[beta] binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of a cancer having at least a partial inflammatory basis.

Description

technical field [0001] The present invention relates to the use of an IL-1β binding antibody or a functional fragment thereof for the treatment and / or prevention of cancer, for example a cancer with at least partly an inflammatory basis. Background technique [0002] Most cancers remain incurable. There is still a need to develop new treatment options for cancer. Contents of the invention [0003] The present invention / disclosure relates to IL-1β binding antibodies or functional fragments thereof (suitably canaginumab, suitably gavozumab) for use in the treatment and / or prevention of cancer (eg having an at least part inflammatory basis cancer) use. Typical cancers, such as cancers with an at least in part inflammatory basis include lung cancer (particularly NSCLC), colorectal cancer (CRC), melanoma, gastric cancer (including esophageal cancer), renal cell carcinoma (RCC), breast cancer, prostate cancer , head and neck cancer (including oral cancer), bladder cancer, hep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/24A61K39/00C07K16/28A61K38/17A61K39/395A61P35/04C07K16/22G01N33/574
CPCC07K16/245C07K16/2818A61K2039/545A61K2039/86A61P35/04C07K2317/76C07K2317/21A61K2039/812A61K2039/507A61K2039/82C07K2317/24A61K2039/505A61K39/39541C07K16/22A61K2039/852A61K2300/00A61P35/00A61K45/06
Inventor M·希克鲁特C·王M·蔡
Owner NOVARTIS AG
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com